Table 1.
Information on the investigated protein. The theoretical Mw is calculated from the primary sequence. Mass recovery is calculated over all the visible UV peaks as described in material and method.
| Type | Provider | Ɛ at 280 nm (mg/ml/cm) | Theoretical MW (kDa) | MALS Mw (kDa) | Mass recovery | pI | Notes | ID |
|---|---|---|---|---|---|---|---|---|
| IgG1λ | AstraZeneca | 1.56 | 144.8 | 144.1 ± 0.2% | 99.9% | 7.96 | — | PPI01 |
| Human IgG1κ | AstraZeneca | 1.47 | 148.2 | 148.1 ± 0.1% | 100% | 8.53 | — | PPI02 |
| Human IgG1κ | AstraZeneca | 1.435 | 144.8 | 144.6 ± 0.2% | 100% | 8.44 | WT IgG | PPI03 |
| IgG1λ YTE | AstraZeneca | 1.755 | 146.2 | 146.5 ± 0.1% | 97.2% | 8.99 | — | PPI04 |
| IgG1κ + scFv | AstraZeneca | 1.57 | 204.4 | 204.4 ± 0.1% | 98% | 9.2 | Bispecific | PPI08 |
| Human IgG1 | AstraZeneca | 1.533 | 144.2 | 144.6 ± 0.2% | 96.5% | 8.95 | — | PPI10 |
| Human IgG1κ | AstraZeneca | 1.66 | 148.9 | 148.7 ± 0.2% | 100% | 9.04 | — | PPI13 |
| IgG2κ | AstraZeneca | 1.31 | 145.1 | 145.6 ± 0.3% | 99.9% | 7.78 | PPI17 | |
| HSA-NEP | AstraZeneca | 1.04 | 146.7 | 146.3 ± 0.1% | 100% | 5.8 | Conjugate | PPI18 |
| Intα-2A | Roche | 0.972 | 19.2 | 20.1 ± 7.5% | 100% | 5.97 | — | PPI30 |